A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NCT00566202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Placebo
DRUG: Escitalopram
DRUG: JNJ-18038683

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.